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Background: Acute myeloid leukemia (AML) is a heterogeneous disorder with aberrant regulation of a variety of
signal pathways. Therefore, simultaneous targeting of two or even more deregulated signal transduction pathways
is needed to overcome drug resistance. Previously, it was reported that SNS-032, a selective cyclin-dependent
kinase inhibitor, is an effective agent for treatment of AML; however, the molecular mechanisms of SNS-032-
induced cell death of AML cells are not yet fully understood. The aim of the study was to characterize the effects in vitro
of SNS-032, used alone and in combination with an Akt inhibitor perifosine, against AML cells and to identify the
mechanism involved.
Results: SNS-032 significantly induced cytotoxicity in human AML cell lines and blasts from patients with newly
diagnosed or relapsed AML. However, Kasumi-1 cells and some of leukemic samples (14.9%) from AML patients were
resistant to SNS-032-mediated cell death. Western blot analysis showed that SNS-032 strongly inhibited the
phosphorylation of mammalian target of rapamycin (mTOR) on Ser 2448 and Ser2481, and that removal of SNS-032
resulted in partial recovery of cell death and reactivation of phosphorylation of mTOR. Moreover, exogenous insulin-like
growth factor-1 (IGF-1) did not reverse SNS-032-induced cell growth inhibition and downregualtion of phosphor-mTOR
at Ser2448 and Ser2481 although slight suppression of IGF-1R expression was triggered by the agent. Furthermore, SNS-
032 at a lower concentration (60–80 nM) enhanced AML cell cytotoxicity induced by perifosine, an Akt inhibitor.
Importantly, SNS-032 treatment reduced colony formation ability of AML cells, which was significantly increased when
two agents were combined. This combination therapy led to almost complete inhibition of Akt activity.
Conclusion: We conclude that SNS-032 might directly target mammalian target of rapamycin complex 1 (mTORC1)/
mTORC2. Our results further provide a rationale for combining SNS-032 with perifosine for the treatment of AML.
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Acute myeloid leukemia (AML) is an aggressive malig-
nancy that can be characterized by rapid growth of a
clonal population of neoplastic cells that accumulate in
the bone marrow as a result of a blockage in
hematopoiesis. In spite of many efforts in the past
decades, the outcome for the patients remains poor. AML
is predominantly a disease of the elderly. Long-term sur-
vival is achieved by approximately 40%-45% of younger* Correspondence: qianwenb@yahoo.com.cn
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reproduction in any medium, provided the orpatient with AML but less than 10% of patients aged >60 -
years [1,2]. Thus new therapeutic approaches should be
explored in the hope of improving outcomes.
AML is a very heterogeneous disease with the constitu-
tive activation of signal transduction pathways that
enhances the survival and proliferation of the leukemic
cells [3]. With marked improvements in our understanding
of the molecular events occurring during the development
of AML, the number of potential targets for therapy has
grown rapidly [4]. For example, numerous small molecular
inhibitors as monotherapy or in combination withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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(FLT-3) inhibitor (sorafenib), farnesyl-transferase inhibitor
(tipifarnib), histone deacetylase inhibitor (vorinostat), as
well as DNA methyltransferase inhibitors (decitabine,
azacitidine), are already on clinical trial for AML [4,5].
The cyclin-dependent kinases (CDKs), a family of serine/
threonine kinases, regulate cell cycle events and some
members are associated with transcription control. CDK
activity is often perturbed in cancer cells but not in human
normal cells. This tumor-specific deregulation makes the
CDKs being a major target for therapy [6,7]. SNS-032 is a
potent and selective inhibitor of CDK2, –7, and −9 [7]. It
has been reported that the antitumor effects of SNS-032
are observed in a variety of solid tumors and hematopoietic
malignancies such as chronic lymphocytic leukemia (CLL)
[8], mantle cell lymphoma (MCL) [9], and chronic myeloid
leukemia (CML) [10]. These studies have led to the phase I
evaluation of SNS-032 as a potential therapy for CLL
and multiple myeloma [11]. More recently, Walsby E, et al.
[12] reported that SNS-032 effectively inhibited
proliferation of NB4, HL-60 cells and fresh AML samples
by inducing a marked dephosphorylation of Ser2 and Ser5
of RNA polymerase (RNA Pol) II carboxy terminal domain
(CTD) and inhibiting the expression of CDK-2, and −9.
Furthermore, cotreatment with SNS-032 and cytarabine
(Ara-c) resulted in remarkable synergy that was associated
with reduced expression of the antiapoptotic genes xIAP,
Bcl-2, and Mcl-1. Although it has been demonstrated that
SNS-032 is capable of inducing cell death in CLL and
MCL cells via inhibition of CDKs that regulate the initi-
ation and elongation of transcription and decrease of the
levels of short-lived proteins such as xIAP, Bcl-2, Mcl-1,
and cyclin D1 [8,9], the molecular mechanisms underlying
the response of the AML cells to SNS-032 are not fully
understood. In this study, we addressed the molecular
mechanisms of the antileukemia action of SNS-032. Our
results show that SNS-032 significantly inhibits cell
proliferation and induces apoptosis in AML cells. However,
some of leukemic cells are resistant to the drug-induced
cell death. Furthermore, we show, for the first time, that
SNS-032 suppresses the levels of mTOR expression and
phosphor-mTOR on Ser2448 and Ser2481. Additionally,
treatment of human AML cells with SNS-032 in combin-
ation with Akt inhibitor perifosine causes enhanced cell
death. This synergistic cytotoxic effect most likely results
from elimination of Akt activation. The findings of the
present study provide a rationale for combining SNS-032
with perifosine for the treatment of AML.
Results
SNS-032-mediated leukemia cell-killing effect
It has been shown that AML and CML cells are sensitive
to SNS-032 [10,12]. We first examined the effect of
SNS-032 on the viability of cultured AML cell lines. Asshown in Figure 1A, the doses that inhibited 50%
proliferation (IC50) at 24 h on cell proliferation in a
panel of 7 AML cell lines ranged from 71.7-402 nM,
with the panel including subtypes M2, M3, M5, and M6
according to the French-American-British (FAB) classifi-
cation. The IC50 in CML K562 cells was 224.3 nM. HEL
cells, however, were found to be resistant with IC50 >
3000 nM. Consistent with these results, colony forma-
tion assay showed that a significant reduction in
clonogenic ability at 50 and 100 nM and a complete ces-
sation of colony formation at 200 nM in HL-60, THP-1,
U937, KG-1, and NB4 cells, but not in Kasumi-1 and
K562 cells. HEL cells were resistant to SNS-032 in
respect to inhibiting colony forming (Figure 1B). We
next evaluated the effects of SNS-032 on the cellular
proliferation of primary leukemic cells. The characteristics
of 47 patients are detailed in Table 1. The majority (85.1%)
of primary AML samples was very sensitive to the drug,
with mean IC50 values for the different FAB types ranging
between 136.2 nM and 186.7 nM (Figure 1C). There was
no significant difference between the response to SNS-032
and the characteristics of AML patients (Table 1). How-
ever, a small fraction (14.9%) of the specimens was rela-
tively resistant to SNS-032-mediated cell death (IC50 >300
nM). Also, a significant decrease in the number of colony
formation was observed in the primary blasts obtained
from 4 patients with newly diagnostic AML (Figure 1D),
but not in the bone marrow cells from healthy volunteers
(Figure 1E).
SNS-032 induced apoptosis and inhibited not only
phosphorylation of RNA Pol II but also phosphorylation
of mTOR and its downstream targets
Previous studies showed that induction of apoptosis is a key
action for SNS-032-induced cell death in AML and CML
[10,12]. We therefore evaluated the effect of SNS-032 on
apoptosis of AML cell lines. Cells were treated with increas-
ing doses of the drug for 24 h, and then apoptotic cells were
determined by annexin V-FITC. The 50% effective concen-
tration (EC50) of KG-1 and HL-60 cell lines was 192.2 and
194.8 nM, respectively. In contrast, HEL cells were resistant
to SNS-032-induced apoptosis. There was little cell death at
24 h after SNS-032 treatment, even at concentration of 200
nM (Figure 2A). To examine the cell cycle effects, HL-60
cells were cultured with SNS-032 or Rapamycin, respect-
ively, and cell-cycle analysis was performed. The cells
exposed to SNS-032 showed accumulations of cells in G1
phase (data not shown), consistent with prior reports [12]
that showing that SNS-032 induces a cell-cycle arrest. The
increased percentages of cells in the G1 phases were also
observed in HL-60 cells treated with Rapamycin. Next, we
set out to unravel the molecular mechanism of action of
SNS-032. On western blot analysis, we observed that SNS-
032 dose-dependently decreased phosphorylation of RNA
Figure 1 SNS-032 potently inhibits cell growth in AML cell lines and primary AML blasts. (A) IC50 of cell lines tested in 24 h by an MTT
assay. Data show mean ± s.d. from three independent experiments, each performed in triplicates. The comments of cell lines are shown. (B) After
treatment with 50, 100, or even 200 nM SNS-032 for 7 days, the ability of colony formation of all tested cell lines were evaluated in
methylcellulose cultures. All data represent an independent experiment from three repeated tests with similar results. Each point is the mean of
triplicates; bar, ± s.d. * represent P < 0.0001; #P = 0.31. (C) IC50 of primary AML cells from the patients with different French-American-British (FAB)
classification subtypes was examined in 48 h by colorimetric assay. (D) Primary leukemic cells from 4 patients with newly diagnostic AML were
treated with SNS-032 (200 nM) and then cultured in methylcellulose medium containing rhSCF, rhGM-CSF and rhIL-3 for 7 days. Colonies were
counted under a microscope. * P = 0.0009; ** P = 0.0005; # P < 0.0001. (E) Human normal mononuclear cells obtained from bone marrow of 5
healthy volunteers were incubated with or without SNS-032, and then cultured in methylcellulose medium for 12 days to detect colony
formation. * represent P > 0.05; # P = 0.0052.
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6 h of incubation (Figure 2B). These are consistent with
the previous report [12]. Interestingly, we found that SNS-
032 strongly inhibited phosphorylation of mTOR on
Ser2448, a marker for mTORC1 activity [13], as well as
phosphorylation of mTOR protein on Ser2481, a marker
for the presence of mTORC2 complexes [13,14]. The ac-
tivity of mTORC1 and mTORC2 in HL-60 and KG-1 cellswas completely inhibited by the treatment with 200 and 400
nM SNS-032 accompanied by slight degradation of protein
expression of mTOR (Figure 2B). The downregulation of
endogenous levels of mTOR protein phosphorylated at
Ser2448 was also confirmed in the treated HL-60 cells using
ELISA assays (Figure 2C). To test the effect of SNS-032 on
unrelated signaling pathways, immunoblotting analysis was
performed (Figure 2D). The addition of the drug did not
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Tyr204 phosphorylation, p38 mitogen-activated protein kin-
ase (MAPK) Thr180/Tyr182 phosphorylation in HL-60
cells, and also did not decrease signal transducer and activa-
tor of transcription 5 (STAT5) Tyr694 phosphorylation and
STAT3 Tyr705 phosphorylation. These data emphasize the
specificity of SNS-032 against mTOR activity.
Moreover, SNS-032 also successfully inhibited phos-
phorylation of 4E-BP1 and p70S6K, the best characterized
targets of mTORC1 (Figure 3A). To test the effect of
SNS-032 on mTORC2 complex, we examined activity of
SGK downstream of mTORC2 by assessing the expression
of phosphor-NDRG1 at Thr346. SNS-032 reduced the
phosphorylation of NDRG1 in a dose-dependent manner
(Figure 2D). Consistently, treatment with this compound
significantly decreased the level of phosphor-Akt (Ser473),Table 1 Patients characteristics
Characteristic Number (%) Mean IC50 (nM) P value
Sex 0.204*
Male 29 (62) 175.0 ± 127.0
Female 18 (38) 138.7 ± 126.1
FAB classification 0.404
M0 4 (9) 186.7 ± 83.7
M1 2 (4) 152.7 ± 89.9
M2 14 (30) 156.4 ± 124.6
M3 9 (19) 136.2 ± 165.2
M4 3 (6) 141.7 ± 116.5
M5 13 (28) 153.1 ± 134.5
M6 2 (4) 289.9 ± 111.8
M7 0 (0)
Type of AML
De novo 44 (94) 154.4 ± 115.6
Relapsed 2 (4) 322.7 ± 326.7
MDS 1 (2) 134.1
Cytogenetic class 0.092
Favorable 8 (17) 114.7 ± 121.3
Intermediate 31 (66) 153.5 ± 121.9
Unfavorable 5 (11) 168.6 ± 134.5
Unknown 3 (6) 143.2 ± 65.7
Flt3 ITD status 0.092
Wild-type 23 (49) 133.1 ± 87.6
Mutated 4 (8) 89.6 ± 63.4
Unknown 20 (43) 207.6 ± 157.9
NPM1 status 0.135
Wild-type 23 (49) 124.7 ± 81.7
Mutated 4 (8) 137.8 ±115.0
Unknown 20 (43) 207.6 ± 158.0
*For comparison, chi-square test was used.which is directly downstream of mTORC2, but its
inhibitory effect on phosphor-Akt (Thr308) was modest
(Figure 3A). To relate the inhibition of activity of
mTORC1/mTORC2 with the induction of cell death, we
investigated that whether removal of SNS-032 correlates
with the recovery from inhibition of phosphor-mTOR and
PARP cleavage, a marker of apoptosis (Figure 3B). Im-
munoblotting analysis revealed that there was a partial
restoration of activity of mTORC1 and mTORC2, as well
as PRAP cleavage. We next used three kinds of kinase
inhibitor LY294002 (targeting PI3K) [15], Rapamycin
(targeting mTORC1) [16], and PP242 (targeting mTORC1/
mTORC2) [17] as positive controls for the inhibition of
mTOR pathway. As shown in Figure 4A, LY294002 (6.25-
50 μM) and PP242 (0.1-2.5 μM) inhibited cell growth of
HL-60 cells in a dose-dependent fashion. In contrast,
Rapamycin (10–80 nM) slightly suppressed cell proliferation.
Immunoblotting analysis showed that Rapamycin decreased
phosphor-mTOR at Ser2448 and mTORC1 substrates in-
cluding p70S6K at Thr389 and 4E-BP1 at Thr37/46.
Whereas, similar to PP242, SNS-032 significantly
inhibited phosphorylation of mTOR at both Ser2448 and
Ser2481, and also suppressed phosphorylation of all
mTORC1/mTORC2 substrates examined (Figure 4B). To-
gether, these data confirm that SNS-032 not only
dephosphorylated Ser2 and Ser5 of RNA polymerase II, it
also inhibited phosphorylation of mTOR.
SNS-032 inhibits IGF-1R and isoform p110δ of PI3K and
reduces the mRNA and protein levels of antiapoptotic
proteins
Since there is an autocrine/paracrine stimulation of
insulin-like growth factor-1 receptor (IGF-1R) in AML
cells, which contribute to activation of PI3K signaling
[18], we determined the protein expressions of IGF-1R
and class I PI3K isoforms after a 6-hour exposure to in-
creasing concentrations of SNS-032 (Figure 5A). The ex-
pression of IGF-1R and p110δ was inhibited by SNS-032
in a dose-dependent fashion. In contrast, p110α protein
levels were not changed. The mRNA expression of IGF-
1R and p110δ (PIK3CD) was also assessed following
treatment with SNS-032 for 6 h using quantitative PCR.
IGF-1R and p110δ mRNA expression were significantly
inhibited by the drug (Figure 5B), suggesting post-
translational effects of SNS-032 on these target proteins.
To investigate whether the suppression of IGF-1R and
cell death induced by SNS-032 could be causally related,
the effects of IGF-1 on SNS-032-induced cell death were
examined. As shown in Figure 5C, exposure of cells to
100 ng/mL IGF-1 did not reverse SNS-032-mediated cel-
lular inhibition. In agreement with this result, addition of
IGF-1 also did not change inhibition of SNS-032 on
phosphorylation of mTOR at both Ser2448 and Ser2481
even though IGF-1 alone upregulated expression of
Figure 2 Induction of apoptosis and inhibition of phosphorylation of RNA Pol II and phosphor-mTOR by SNS-032. (A) HL-60, KG-1 and
HEL cells were treated with SNS-032 for 24 h, and apoptosis was assessed by flow cytometry after staining of the cells with annexin V-FITC and
propidium iodide. (B) Three AML cell lines were treated with SNS-032 at the indicated doses for 6 h. PBS was used as a negative control. The
total cell lysates (50 μg of protein per lane) were analyzed by Western blotting with antibodies against RNA pol II, RNA pol II carboxy terminal
domain phosphor-serine 2 and phosphor-serine 5, mTOR, phosphorylated form of mTOR on Ser2448 and Ser2481. Anti-β-actin was used as a
loading control. (C) HL-60 cells were treated SNS-032 at the indicated doses for 6 h. The endogenous levels of mTOR protein phosphorylated at
Ser2448 and were detected using solid phase sandwich enzyme-linked immunosorbent assay. (D) HL-60 cells were treated with SNS-032 (50–400
nM for 6 h). whole-cell lysates were subjected to Western blotting to assess phosphorylation and protein expression of NDRG1, p38MAPK, STAT3/5,
and ERK1/2.
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Figure 3 SNS-032 strongly inhibits expression and phosphorylation of downstream targets of mTOR, and removal of SNS-032
correlates with the recovery from inhibition of phosphor-mTOR and cell death. (A) Exponentially growing cells exposed to the indicated
doses SNS-032 for 6 h and then cell lysates were prepared, and 50 μg of total cell extracts was separated in 6-12% SDS-PAGE. Protein bands were
detected with antibodies to phosphor-Akt (Ser437/Thr308), Akt, phosphor-4E-BP1 (Ser65/Thr37/46/Thr70), 4E-BP1, phosphor-p70S6K (Thr389),
p70S6K, and actin. This experiment was repeated once with identical results. (B) KG-1 cells were treated with 100 nM SNS-032 for 6 h, and then
divided into two parts. One was washed into fresh medium without the drug, whereas the other was continuing to culture without washing. The
cells were collected at the indicated times for Western blot analysis.
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hypothesis that SNS-032 might directly target mTORC1/
mTORC2 pathway.
The mTORC1 pathway is well known to stimulate
protein synthesis [19]. We therefore tested the effects of
SNS-032 on the levels of antiapoptotic proteins in HL-
60 and KG-1 cell lines using Western blot analyses. Of
antiapoptotic proteins, xIAP, cIAP-1, and Mcl-1 were
significantly down-regualted and Survivin was slightlyinhibited; however, Bcl-2 was unchanged after SNS-032
treatment (Figure 6A). We then measured mRNA ex-
pression of these proteins using real time RT-PCR. Con-
sistent with previous reports [8,12], SNS-032 also
induced a dose-dependent reduction of mRNA of these
genes (range, 84.1-96.3% decrease at 200 nM) for HL-60
cells. Similar results were obtained with KG-1 cells
(Figure 6B). We further wished to know whether
Rapamycin treatment also reduce anti-apoptotic proteins
Figure 4 Effect of SNS-032, PP242, Rapamycin, and LY294002 on phosphorylation of mTORC1 and mTORC2 substrates in HL-60 cells.
(A) HL-60 cells were treated with LY294002, Rapamycin, and PP242, respectively, at the indicated doses for 24 h. The anti-proliferative effects were
measured by an MTT assay. The values are expressed as means ± SEM from three independent experiments. (B) HL-60 cells were treated for 6 h
with LY294002 (25 μM), Rapamycine (10 nM), PP242 (2.5 μM), and SNS-032 at 50, 100, 200 and 400 nM, respectively. Whole cell lysates were then
subjected to SDS-PAGE followed by immunoblotting with antibody that recognizes the corresponding antigen.
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compound slightly downregulated xIAP expression but
did not change expression of Survivin. Despite marked
reduction of phosphor-mTOR at Ser 2448, Rapamycin
upregulated expression of phosphor-Akt (Ser473)
(Figure 6C), which might explain why AML cells were
relatively resistant to Rapamycin, even at the higher con-
centration of 80 nM (Figure 4A).
Perifosine sensitizes AML cell lines and primary cells to
SNS-032-mediated cell death
Given the fact that mTOR inhibition activates PI3K/Akt
in AML cells [20], we determined whether perifosine, an
Akt inhibitor, enhances SNS-032-mediated cell death.
For this, we treated KG-1 and NB4 cells with a series of
doses of SNS-032 or/and perifosine. As demonstrated in
Figure 7A, treatment of KG-1 and NB4 cells with SNS-
032 plus perifosine resulted in significantly lower cell
viability than either SNS-032 or perifosine treatment.
The combination index analysis showed synergistic cyto-
toxic effects when two drugs were combined at relatively
higher concentrations. Next, whether perifosine
enhances the effect of SNS-032 in long-term colonyformation assay was also examined. We observed that,
under the conditions when SNS-032 or perifosine alone
had moderate inhibition effect of colony formation of
leukemic cell lines the combination therapy almost com-
pletely suppressed the colony-forming ability of these
leukemic cells (Figure 7B). Similar results were also
found in primary blasts obtained from 2 patients with
AML (Figure 7C). To further delineate the effect of
combination treatment on growth signaling, we
examined the effect of SNS-032, perifosine, and combin-
ation on the activiation of caspase pathway, phosphorylation
of mTOR and downstream targets, as well as expression of
phosphor-ERK1/2. As shown in Figure 7D, we found that al-
though SNS-032 and perifosine alone had little effect on
caspase 3 and PRAP, the two together were highly effective,
suggesting that perifosine can enhance SNS-032-induced
apoptosis. Several studies have shown that perifosine inhibits
activation of Akt in cancer cells [21,22]. Consistent with
these reports, perifosine significantly inhibited the level of
phosphorylated Akt (Ser473/Thr308) in KG-1 and NB4 cells
and consequently decreased the level of phosphorylated
mTOR (Ser2448), which represent the activity of mTORC1,
but not that of phosphorylated mTOR (Ser2481). Whereas,
Figure 5 SNS-032 reduces expression of IGF-1R and PI3K isoform p110δ and IGF-1 does not reverse SNS-032-mediated cellular
inhibition. (A) HL-60 and KG-1 cells were cultured with increasing concentrations of SNS-032. At 6 h after treatment, cells were harvested and
lysed, and expression of IGF-1R and PI3K isoforms p110α and p110δ was determined by Western blot analysis. Actin was used as protein loading
control. (B) The levels of IGF-1R and PIK3CD mRNA was determined after 6 hours-exposure of SNS-032 by real-time quantitative RT-PCR, and
expressed as relative levels compared with controls. (C) Three AML cell lines were treated with 100 nM SNS-032 for 24 h, with or without IGF-1
(100 ng/mL) preincubation for 3 h, and then cell viability was examined by an MTT assay. All values represent the mean of experiments in
triplicate; bar, ± s.d. (D) HL-60 cells were treated with SNS-032, or combined with IGF-1. Protein expression of IGF-1R, total and phosphorylated
forms of mTOR was analyzed by Western blot. Actin levels were used as loading control.
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and NB4 cells at the low concentrations of 60 and 80 nM of
SNS-032, respectively. Importantly, combined SNS-032 and
perifosine therapy resulted in almost complete elimination
of phosphorylated Akt (Ser473/Thr308) and activity of
mTORC1. Consequently, it also significantly attenuated 4E-
BP1 phosphorylation at all tested sites (Thr37/46, Thr70,
and Ser65) and phosphorylated p70S6K (Thr389), both of
which are direct target of mTORC1. Together, this combin-
ation treatment is likely to have significant benefit to AML
patients as it can synergistically inhibit activity of mTORC1
and Akt in leukemic cells.
Discussion
CDK inhibitors are gaining success in the clinic as
antitumor agents for cancers including hematologic ma-
lignancies [11,23]. SNS-032 is a potent CDK inhibitor,
which targets CDK2, CDK7, and CDK9, the CDKs that
regulate the initiation and elongation of transcription by
phosphorylating Ser2 and Ser5 of RNA Pol II, respect-
ively. These biologic effects are attributed to the inhibi-
tory activity against CLL [8,11] and MCL cells [9], whichwas also demonstrated in AML cells [12]. This study
investigated the actions of SNS-032 in AML cells. Our
results showed that SNS-032 was active against majority
of the tested AML cell lines and primary leukemic cells.
However, its mechanisms of action seem to be
dependent on the molecular context of the disease. We
found that in addition to the typical inhibitory effect on
phosphorylation of RNA pol II, SNS-032 caused reduc-
tion of activity of mTORC1 and mTORC2, as evidenced
by dephosphorylation of mTOR on Ser2448 and
Ser2481, without strongly inhibiting PI3K, ERK/MAPK,
and STAT3/5. Consistent with these results, SNS-032
treatment elicited potent suppression of phosphorylation
4E-BP1 and p70S6K, the downstream targets of
mTORC1, in AML cells and also reduced phosphor-Akt
on Ser473, a substrate of mTORC2. Crucially, the effects
of SNS-032 in AML cells were partially reversible after
drug removal, suggesting the necessity of sustained in-
hibition of the activity of mTORC1 and mTORC2 for
cell killing.
The mTOR is part of two distinct cellular protein
complexes, mTORC1 and mTORC2, which plays an
Figure 6 SNS-032 significantly reduces the expression of anti-apoptotic proteins in AML cells. (A) HL-60 and KG-1 cell lines were treated
with SNS-032 at the indicated doses for 6 h. Cell lysates were fractionated on 6-12% SDS-polyacrylamide gels and analyzed by Western blotting
with antibodies against xIAP, cIAP-1, Survivin, Mcl-1, Bcl-2 and actin. (B) AML cell lines were treated with SNS-032 at the indicated doses. After 6 h
treatment, mRNA levels of the indicated genes were measured by real-time RT-PCR. The results are presented as the ratios of mRNA expression in
treated cells in relation to the amount present in untreated cells (mean of ± s.d. mRNA from 3 different experiments). (C) HL-60 cells were treated
with Rapamycin at the indicated doses for 6 h. Equal amounts of protein were resolved by SDS-PAGE and immunoblotted with the
indicated antibodies.
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Figure 7 Combination of SNS-032 with perifosine strongly inhibits phosphor-Akt and enhances cytotoxicity against AML cells. (A) KG-1
and NB4 cells were treated with a series of dilutions of each agent individually and with both compounds simultaneously in a fixed ratio (1:50)
for 24 h and cell growth was determined by an MTT assay. Values represent the mean plus or minus s.d. of triplicate experiments. The
combination index (CI) was calculated by Calcusyn software (lower panel). (B) KG-1 and NB4 cells were treated with SNS-032, perifosine, or
combination, and then plated in triplicate, at a density of 2000 cells/ml in methylcellulose medium. Colony counts at 7 days are shown as the
average of three independent experiments; bar, ± s.d. (C) The primary AML cells from 2 patients were treated with two agents alone or in
combination followed by cultured in methylcellulose medium. The number of leukemic colony at 7 days was counted. The data are shown as
the means of triplicate experiment. (D) AML cell lines were incubated with or without SNS-032, in the presence or absence of perifosine. At 6 h
later, cell lysates were prepared, and activation of caspase-3 and cleavage of PARP were examined by Western blot analysis. The expression and
phosphorylation of ERK1/2, Akt, mTOR, and its downstream targets were also determined. The difference in the level of protein expression was
semi-quantitatively determined by densitometry and expressed as a ratio. Actin was used as protein loading control.
Meng et al. Journal of Hematology & Oncology 2013, 6:18 Page 10 of 14
http://www.jhoonline.org/content/6/1/18important role in the translational control, modulation
of metabolic pathways, regulation of cell cycle, and
modulation of apoptosis [24]. The constitutive activation
of the mTORC1 was found in AML cells, which is inde-
pendent of PI3K/Akt pathway [25,26]. Also the presence
and activity of mTORC2 was demonstrated in the cell
lines and primary blasts of AML [27]. Thus, mTORC1/
mTORC2 pathways provide a promising target for AML
therapy. In fact, the efficacy of rapamycin and its analogs
RAD001, CCI-779 (temsirolimus), and AP23573 (deforolimus)
that inhibit mTORC1 complex has been investigated in
various experimental and clinical studies in AML [28]. Unfor-
tunately, only limited therapeutic effects were observed in clin-
ical trials. The reason for this might be induction of Aktactivity because the drugs do not acutely inhibit mTORC2
[20,28,29], and rapamycin is an incomplete inhibitor of
mTORC1 [30]. Recently, dual targeting of mTORC1/2 has
been demonstrated to be much more effective than treatment
with rapamycin in blocking the growth of AML cells and to
have potent cytotoxic activity against AML progenitors
in vitro [17,27,30,31], suggesting that dual inhibition of
mTORC1/2 is a new therapeutic strategy for the treatment of
AML. In the present study, the effects on levels of mTOR
phosphorylated on Ser2448 and Ser2481 in AML cells by
treatment with 200 nM SNS-032 was impressive, with a
complete elimination after 6 h of treatment. PI3K signaling
pathway is essential for activation of mTOR [28]. Constitutive
activation of class I PI3K isoforms has been commonly
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expressed at a high level in leukemic cells from AML while
other isoforms are only up-regulated in the cells from some
patients [28,32]. Our studies revealed that 200–400 nM
SNS-032 slightly inhibited protein expression of
p110δ, but not that of p110α. Moreover, there was
decrease in the expression of IGF-1R after exposure
to equivalent concentrations of SNS-032. As a constitu-
tively activated IGF-1R is expressed in AML cells and
IGF-1/IGF-1R signaling contributes to deregulated PI3K
activity [18,33], we investigated whether exogenous IGF-1
stimulation reverses SNS-032-induced cell death. We
show here that IGF-1 did not affect not only inhibition of
cell growth but also downregulation of phosphor-mTOR
at Ser2448 and Ser2481 by SNS-032 in AML cells. Col-
lectively, these data suggest that SNS-032 might directly
target mTORC1/mTORC2.
AML is a heterogeneous disease with aberrant regula-
tion of various signal pathways. Thus, simultaneous
targeting of two or even more deregulated signal trans-
duction pathways is needed to overcome drug resistance.
A recent study of phase I trial of SNS-032 showed that
its plasma concentration reached 300 nM when the drug
was administered intravenously in the patients with
lymphoma who received total doses of 75 mg/m2 [11].
In this study, we observed that HEL cells were resistant
to SNS-032. Meanwhile, Kasumi-1 cells and the primary
blasts from a few AML patients were found to be rela-
tively resistant with IC50 > 300 nM. The mechanisms by
which AML cells are resistance to SNS-032 remain un-
clear. Given these observations and the fact that mTOR
inhibition activates PI3K/Akt in AML cells [20], we
postulated that Akt inhibitors might act synergistically
with SNS-032 in treating leukemia. Our results show
that lower concentrations of perifosine sensitized AML
cells to low doses SNS-032-induced cell growth inhib-
ition in vitro. Importantly, perifosine and SNS-032
reduced colony formation ability, which was almost
completely eliminated when the two treatments were
combined. Moreover, this combination treatment resulted
in significant downregulation of phosphor-Akt (Ser 437
and Thr308), compared with using either agent alone. As
our results were being prepared for submission, a new re-
port shows that combination of perifosine with mTORC1
inhibitors lead to an enhanced antitumor efficacy in vitro
and in vivo most likely via activation of GSKβ [34]. Previ-
ously, we and other demonstrated that perifosine
induced apoptosis in AML cell lines [35] and primary
cells [36] but not affect normal CD34+ stem cells
[36]. Recently, perifosine have entered phase 2 clinical
trials for solid tumors and hematologic malignancies
including leukemia [28,37]. These data provide a ra-
tionale for the combination therapy with SNS-032
and perifosine as a novel approach for treating AML.Conclusions
In summary, results in the present study show that SNS-
032 is a potential agent for inhibiting cell growth and
suppressing of mTORC1/mTORC2 activity in AML cells.
Furthermore, synergistic inhibitory effects in vitro by the
combination of SNS-032 and Akt inhibitor perifosine
were observed at relatively lower concentrations. This
combination treatment led to almost complete inhibition
of Akt activity. Collectively, we have identified a novel
mechanism of action of SNS-032. Our results suggest the
possibility of combining SNS-032 with perifosine in a
regimen that would optimize the antileukemic activity
against cancer cells that are resistant to mTOR inhibitor-
induced cell death.
Materials and methods
Cell lines, leukemia patient samples, and reagents
Leukemic blasts and normal bone marrow cells were
freshly isolated from bone marrow of patients with
newly diagnosed, or refractory/relapsed AML (n = 47)
and healthy volunteers (n = 5), respectively, after
informed consent was obtained using guidelines
approved by the Ethics Committee of Zhejiang Univer-
sity the First Affiliated Hospital. CML cell line K562 and
AML cell lines HL-60, U937, NB4, THP-1, MV4-11, and
HEL were purchased from the American Type Culture
Collection (ATCC; Manassas, VA, USA). Kasumi-1 and
KG-1 cell lines were gifts from Prof. S Chen (Shanghai
Jiaotong University, Shanghai, China) and Prof. R Xu
(Zhejiang University, Zhejiang, China), respectively. The
primary leukemic cells and cell lines were maintained in
Dulbecco modified Eagle medium (DMEM) or RPMI-
1640 (Gibco-RRL, Grand Island, NY, USA), respectively,
supplemented with heat inactivated fetal bovine serum
(FBS) at 37°C in a 5% CO2 humidified incubator.
SNS-032 and Rapamycin were purchased from Selleck
Chemicals (Houston, TX, USA) and dissolved in
dimethylsulfoxide (DMSO) at 1 mg/mL, and then stored
at −20°C in small aliquots. Perifosine obtained from
Selleck was prepared as a 1 mg/mL stock solution in
sterile water and stored at −20°C. IGF-1 was purchased
from Peprotech (Rocky Hill, NJ, USA). LY294002 and
PP242 were purchased from Sigma (St Louis, MO,
USA). Stock solutions of these agents were subsequently
diluted with serum-free RPMI-1640 medium prior to
use. In all experiments, the final concentration of DMSO
did not exceed 0.1%.
MTT colorimetric survival assay
Cell viability was monitored by 3-(4,5-dimethylthiazol-
2-yl) -2,5-diphenyltetrazolium bromide (MTT; Sigma)
assay. Briefly, cell lines (2 × 104 cells/well) and primary
leukemic cells (1 × 105 cells/well) were seeded in 96-well
plates and treated with SNS-032 (50–400 nM) for the
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MTT solution (5 mg/mL) was added to each well and
then the samples were incubated at 37°C for 4 h. The
absorbance of the reaction was measured at 570 nm by
spectrophotometry. IC50 values (the concentration of
drug required to kill 50% of the cells) were calculated.
Colony-forming assay
The effects of SNS-032, perifosine, or combination on the
leukemia colony formation (CFU-L) in methylcellulose
medium (Sigma) were examined using leukemic colony
assay as previously described [38]. Briefly, leukemic cells
(2 × 103) in 600 μL of methylcellulose solution were
incubated in the presence of the agents or an equivalent
amount of medium at 37°C in a humidified atmosphere
with 5% CO2. Primary leukemic cells were cultured in
methylcellulose medium containing recombinant human
(rh) stem cell factor (SCF), granulocyte macrophage-
colony-stimulating factor (GM-CSF), and interleukin 3
(IL-3, Peprotech) at 2 × 104 cells/dish. After 7 days, CFU-
Ls that contain >40 cells were scored manually under a
light microscope (Olympus, Tokyo, Japan). For colony
assay of human normal bone marrow cells, 3 U/mL rh
erythropoietin (Peprotech), 50 ng/mL rhSCF, 30 ng/mL
rhGM-CSF, and 10 ng/mL rhIL-3 were added to the
methylcellulose medium. The colonies were counted
under a microscope on day 12 of culture.
Flow cytometric analysis
HL-60, KG-1 and HEL cells were treated with SNS-032
at concentrations between 50 and 200 nM for 24 h.
Apoptotic cells were quantified by Annexin V-FITC and
propidium iodide (PI) double staining using a detection
kit purchased from Biouniquer (Jiangsu, China)
according to the manufacturer’s instructions.
Western blot analyses
Cells were incubated for 6 h in the presence or absence
of the drugs. The cells were then lysed at 4°C in lysis
buffer. Protein concentration was determined by the
bicinchoninic acid (BCA) method. The total protein wasTable 2 Sense and antisense primers for amplification of the








18 s rRNA 50-GTAACCCGTTGAACCCCATused for Western blot analysis as previous described
[35]. Aliquots containing 50 μg proteins were separated
on sodium dodecyl sulfate (SDS)-polyacrylamide gels
containing 6-12% acrylamide gradients and then
transferred to polyvinylidene difluoride membranes
(Millipore, Billerica, USA). The membranes were
blocked for 2 h in Tris-buffered saline containing 0.1%
Tween and 5% nonfat dry milk and then incubated with
primary antibodies overnight at 4°C, followed by incuba-
tion with secondary antibodies conjugatesd with fluores-
cent dyes for 2 h at room temperature. After washing
three times, the membranes were incubated with anti-
rabbit/mouse IgG conjugated to horseradish peroxidase.
The results were visualized with the ECL detecting kit.
All primary antibodies were purchased from Cell Signal-
ing Technology (Beverly, MA, USA), except the human
anti-RNA poly II, RNA poly II CTD phospho-Ser2 and
phospho-Ser5 (Abcam, Cambridge, UK), and phospho-
Akt (Thr308), PI3K p110δ (Eptomics, Burlingame,
California, USA) primary antibodies.
Enzyme-linked immunosorbent assay
The enzyme-linked immunosorbent assay (ELISA) to de-
tect endogenous levels of mTOR protein phosphorylated
at Ser2448 was performed in 96-well plates using
PathScan Phospho-mTOR Sandwich ELISA Kit purchased for
Cell Signaling Technology according to the manufacturer’s
protocol.
Real-time PCR
Total RNA was extracted using an RNeasy Plus kit
(TaKaRa Shuzo, Kyoto, Japan). Each cDNA template was
made from total RNA with reverse transcriptase kit
according to manufacturer’s instructions (Invitrogen,
Carlsbad, CA, USA). Amplification reactions were
performed using SYBRW Premix Ex Taq™ (TaKaRa
Shuzo) in a 25 μL volume on a 96-well optical reaction
plate in the iQ5 Multicolor Real-time PCR Detection
System (Bio-Rad, Hercules, CA, USA). The following
cycling parameters were used: 30 seconds at 95°C for
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total of 40 cycles. The fold change in mRNA was
calculated by the 2-ΔΔCt method. All samples were
normalized to 18 s ribosomal RNA, an RNA polymerase
I transcript that is not modulated by inhibition of RNA
pol II. Primer sequences were shown in Table 2.
Statistical analysis
One-way analysis of variance followed by the Tukey test,
or Student’s test was performed using the GraphPad Prism
5.0. P-values that were less than 0.05 were considered
statistically significant. Synergisms in the combination
treatments were analyzed using CalcuSyn software (Biosoft,
Cambridge, UK). The data were expressed as log10 (CI)
versus fraction affected. By this method, log10 (CI) <0
indicates a synergistic.
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